NCT04755894View on ClinicalTrials.gov

HDDO-1756 Bio Equivalence Study

PHASE1CompletedINTERVENTIONAL
Enrollment

56

Participants

Timeline

Start Date

June 12, 2020

Primary Completion Date

June 19, 2020

Study Completion Date

July 27, 2020

Conditions
Hyperlipidemias
Interventions
DRUG

HDDO-1756

single dose

DRUG

HDDO-17561/HDDO-17562

single dose

Trial Locations (1)

Unknown

Hyundai Pharm, Seoul

Sponsors
All Listed Sponsors
lead

Hyundai Pharmaceutical Co., LTD.

INDUSTRY